Diabetes Care Center, King Salman Bin Abdulaziz Hospital, Riyadh 12769, Saudi Arabia.
Biochemistry Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
Diabetes Res Clin Pract. 2021 Feb;172:108538. doi: 10.1016/j.diabres.2020.108538. Epub 2020 Nov 13.
This retrospective study aimed to characterize comorbidities and associated with mortality among hospitalized adults with Covid-19 managed as perthe Saudi Ministry of Health protocol in a specialized tertiary hospital in Riyadh, Saudi Arabia. Medical records of 300 adult patients with PCR-confirmed SARS-CoV2 infection and admitted in King Salman Hospital (KSH) from May 1 to July 31, 2020 were included. Medical history, management and outcomes were noted. Males significantly outnumber females (259 versus 41). South Asians comprise 41% of all admitted patients. Mortality rate was 10% and highest among Saudi males (28.9%). Type 2 diabetes mellitus (T2DM) was the most common comorbidity (45.7%). Almost all patients (99%) had pneumonia. Patients > 50 years were three times more likely to die (confidence interval, CI 1.3-6.9; p = 0.01) from Covid-19. Congestive heart failure (odds ratio OR 19.4, CI-1.5-260.0; p = 0.02) and acute kidney injury (OR 11.7, CI-4.7-28.6; p < 0.001) were significantly associated with higher mortality. Dexamethasone use significantly improved the final outcome based on net reclassification improvement (NRI) and integrated discrimination improvement (IDI) (p < 0.05). In this single-center study, T2DM was very common among hospitalized Covid-19 patients. Patients > 50 years, those with congestive heart failure and acute kidney injury are at higher risk for worse Covid-19 outcome.
这项回顾性研究旨在描述沙特阿拉伯利雅得一家专门的三级医院中,根据沙特卫生部协议管理的住院成人 COVID-19 合并症,并分析其与死亡率的关系。研究纳入了 2020 年 5 月 1 日至 7 月 31 日期间在 King Salman 医院(KSH)住院的 300 名 PCR 确诊的 SARS-CoV2 感染的成年患者的病历。记录了患者的病史、治疗方法和结局。男性明显多于女性(259 比 41)。南亚人占所有住院患者的 41%。死亡率为 10%,其中沙特男性最高(28.9%)。2 型糖尿病(T2DM)是最常见的合并症(45.7%)。几乎所有患者(99%)都患有肺炎。年龄>50 岁的患者死于 COVID-19 的风险增加了三倍(置信区间,CI 1.3-6.9;p=0.01)。充血性心力衰竭(OR 19.4,CI-1.5-260.0;p=0.02)和急性肾损伤(OR 11.7,CI-4.7-28.6;p<0.001)与更高的死亡率显著相关。根据净重新分类改善(NRI)和综合鉴别改善(IDI),地塞米松的使用显著改善了最终结局(p<0.05)。在这项单中心研究中,T2DM 在住院 COVID-19 患者中非常常见。年龄>50 岁、充血性心力衰竭和急性肾损伤的患者 COVID-19 结局更差的风险更高。